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Background: Chronic hepatitis C virus (HCV) infection is frequently associated with extrahepatic autoimmune
disorders while interferon (IFN) and ribavirin treatment may exacerbate these conditions. Autoantibodies from HCV
patients identify a novel indirect immunofluorescence (IIF) pattern on HEp-2 cells characterized by cytoplasmic rods
and rings (RR). Our objectives were to determine the prevalence and clinical associations of RR autoantibodies in
HCV patients, and identify related novel autoantibody targets.
Methods: Sera from 315 patients with HCV (301 treatment naive, 14 treated with interferon and/or ribavirin) were
analyzed for the presence of RR antibodies by IIF on commercially available HEp-2 cell substrates. Antibodies to
inosine monophosphate dehydrogenase 2 (IMPDH2) and cytidine triphosphate synthase 1 (CTPS1) were detected
by addressable laser bead assay and other potential targets were identified by immunoscreening a protein
microarray. Clinical and demographic data including HCV genotype, mode of infection, prior antiviral therapy, and
histological findings were compared between RR antibody positive (RR+) and negative (RR-) patients.
Results: The median age of the HCV cohort was 51 years, 61% were male, and 76% were infected with HCV
genotype 1 (G1). Four percent (n=14) had been treated with IFN-based therapy (IFN monotherapy, n=3; IFN/
ribavirin, n=11); all had a sustained virologic response. In total, 15 patients (5% of the cohort) were RR+. RR+ and
RR- patients had similar demographic and clinical characteristics including age, sex, mode of HCV infection,
prevalence of the G1 HCV genotype, and moderate to severe fibrosis. Nevertheless, RR+ patients were significantly
more likely than RR- cases to have been treated with IFN-based therapy (33% vs. 3%; adjusted odds ratio 20.5 [95%
confidence interval 5.1-83.2]; P<0.0005). Only 1/10 RR positive sera had detectable antibodies to IMPHD2 and none
had antibodies to CTPS1. Potentially important autoantibody targets identified on protein arrays included Myc-
associated zinc finger protein (MAZI) and ankyrin repeat motif.
Conclusion: The majority of HCV patients with RR autoantibodies previously received IFN/ribavirin antiviral therapy.
Further studies are necessary to determine the genesis of intracellular RR and elucidate the clinically relevant
autoantigens as well as the clinical and prognostic significance of their cognate autoantibodies.Background
An estimated 180 million people worldwide are infected
with hepatitis C virus (HCV), a known major cause of
chronic liver disease [1,2]. HCV infection is also associ-
ated with several immunological abnormalities, including
the production of both organ specific and non-organ spe-
cific autoantibodies [3-5]. Organ specific autoantibodies* Correspondence: fritzler@ucalgary.ca
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reproduction in any medium, provided the orinclude those directed against targets in pancreatic islet
cells [6], thyroid [7-9], adrenal cortex [6] and gastric par-
ietal cells [10]. Non-organ specific autoantibodies include
anti-nuclear antibodies (ANA), anti-smooth muscle anti-
bodies (ASMA), anti-mitochondrial antibodies (AMA),
anti-neutrophil cytoplasmic antibodies (ANCA), and anti-
liver/kidney microsomal antibodies (LKM) [11-14]. Al-
though their clinical significance remains unclear, ANA
have been reported in 4% to 63% of patients with chronic
hepatitis C [11,15-18]. Some studies have shown that
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sponsiveness to antiviral treatment [19-23]. Other reports
have found no differences in these and other clinical pa-
rameters [17,24-28]. Interferon (IFN) and ribavirin, cor-
nerstones of the management of HCV infection, have
immunomodulatory effects [29,30] such as the production
of autoantibodies [31].
In patients with chronic hepatitis C infection, a novel
cytoplasmic autoantibody pattern (RR) characterized by
rods (~3-10 μm in length) and rings (2–5 μm diameter)
has been described on HEp-2 cells [32-34]. Inosine
monophosphate dehydrogenase 2 (IMPDH2) and cyti-
dine triphosphate synthase 1 (CTPS1) were identified as
potential autoantibody targets localized to the RR struc-
tures [32,33]. The objectives of this study were to deter-
mine the prevalence and clinical associations of RR
autoantibodies in chronic hepatitis C patients, to exam-
ine the frequency of antibodies to IMPDH2 and CTPS1
and to identify other potential autoantibody targets by
screening high density peptide and protein arrays.
Methods
Study cohort
The study cohort included 315 chronic HCV patients
followed at the University of Calgary Liver Unit. Three
hundred one (301) treatment-naïve patients, all of whom
had percutaneous liver biopsies, participated in a study
evaluating novel serum biomarkers of liver fibrosis. Sera
from these patients were collected prior to liver biopsy
and stored at −80°C. The remaining 14 patients were in-
volved in a study evaluating the prevalence of occult
HCV and hepatitis B infection. All patients had achieved
a sustained virologic response (SVR) to anti-HCV ther-
apy as defined by undetectable HCV RNA 6 months fol-
lowing interferon and/or ribavirin treatment [35]. The
sera from these patients were collected after therapy.
Clinical and demographic data including age, gender,
HCV genotype, mode of HCV acquisition, prior antiviral
therapy, biochemical data, and histological findings were
obtained by a retrospective review of medical records.
Sera from 100 primary biliary cirrhosis (PBC) [36] and
27 systemic lupus erythematosus (SLE) patients were
used as controls. The study protocol was conducted in
accordance with the Conjoint Health Ethics Review
Board at the University of Calgary.
Indirect Immunofluorescence (IIF)
Serum samples were analyzed for autoantibodies at the
Mitogen Advanced Diagnostics Laboratory, University of
Calgary (http://www.mitogen.ca). RR autoantibodies [37]
were detected by IIF on HEp-2 cells (human laryngeal
carcinoma cell line: INOVA Diagnostics, Inc.; San Diego,
CA) using the manufacturer’s protocol, which included
serum diluted to 1/160 and a heavy chain-specific,fluorescein-conjugated goat anti-human immunoglobulin
IgG as the secondary antibody. For comparison purposes,
sera were also tested on a HEp-2 substrate from another
manufacturer (ImmunoConcepts Inc., Sacramento, CA)
using their recommended protocol. In addition to the RR
pattern, other IIF patterns (e.g. ANA, AMA) were also
recorded. All slides were viewed by an experienced tech-
nologist on a Zeiss Axioshop 2 Plus microscope (Carl
Zeiss Inc., Thornwood, NY) fitted with appropriate filters.
Images were recorded using a Zeiss Axiocam HRc digital
camera and Zeiss Axiovision (version 3.1) software.
Digital images were processed using Photoshop Version
12.1 (64 bit).
Tissue culture cells
HEp-2 (Dr. Edward K.L Chan, University of Florida) and
HeLa (human cervical cancer; American Type Culture
Collection (ATCC: Manassas, VA) cells were cultured in
DMEM containing 10% Fetal Bovine Serum (FBS) and 1%
penicillin-streptomycin; CHO (Chinese hamster ovary;
ATTC) cells were grown in RPMI 1640 with 10% FBS and
1% penicillin-streptomycin media. All cells were cultured
on glass slides or cover slips in a 37°C incubator under 5%
CO2. Before cells reached confluence, they were fixed and
permeabilized with a variety of fixatives including 3.5%
paraformaldehyde at room temperature for 30 minutes
followed by a rinse in phosphate buffered saline (PBS) and
then permeabalized with 0.5% Triton X100. Other organic
fixatives included ice-cold acetone, methanol and a
methanol-acetone mixture (3:1 volume:volume) for
15 minutes followed by air drying the slides to at
room temperature. The nuclei of CHO cells were
counterstained with 4′,6-diamidino-2-phenylindole
(DAPI). In an attempt to determine the tissue culture
conditions that were responsible for the RR pattern,
HEp-2 and HeLa cells were treated with ribavirin
(Sigma-Aldrich; R9644) at a concentration of 1 μM
for 1–3 hours as previously reported [33]. These cell
preparations were then processed for IIF using the re-
agents and protocols as described above for the HEp-2
slides obtained from Dr. Edward K.L. Chan.
IMPDH2 and CTSP1 immunoassay
Purified, full length human IMPDH2 (Abnova; Taipei City,
Taiwan) and full length recombinant CTSP1 (NOVUS
Biologicals, Littleton, CO, USA: Catalogue # AAH09408)
were covalently coupled to addressable laser beads
(Luminex Corporation, Austin, TX) as previously de-
scribed [36]. These coupled beads were then used to de-
velop an immunoassay with respective monoclonal
antibodies (Abcam; Cambridge, MA) as the positive
markers and normal human sera as negative controls
using a Luminex 200 fluorometer (Luminex Corp.)
according to previously published protocols [38].
Table 1 Demographic, clinical, and autoantibody features
of the study population (n=315)
Characteristic Frequency (N)*
Demographics
Median age, yrs 51 (45–54)
Male gender 61% (193)
HCV genotype
1 76% (239)
2 and 3 18% (58)
Other/unknown 6% (18)
Mode of HCV infection
Injection drug use 45% (141)
Blood transfusion 19% (59)
Prior HCV treatment 4% (14)
Interferon monotherapy 21% (3/14)
Interferon and ribavirin 79% (11/14)
Biochemical data †
ALT, IU/L 64 (42–110)
Platelets, x109/L 200 (163–243)
Histologic characteristics
A2-3 necroinflammation 72% (226)
F2-4 fibrosis 66% (208)
Cirrhosis (F4) 9% (27)
Autoantibodies
RR positive 5% (15)
ANA positive 89% (281)
Anti-mitochondrial antibody positive 2% (5)
* All data are median (IQR) or proportions (%, n).
† ALT and platelets missing in 10 and 5 patients, respectively.
Abbreviations – ANA, antinuclear antibodies; AMA, anti-mitochondrial
antibodies; RR, Rods and Rings.
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Human peptide arrays containing ~30,000 proteins spot-
ted in duplicate on solid phase membranes (imaGenes,
Berlin, Germany) were screened by an immunoblotting
protocol provided by the manufacturer using two RR
index sera and normal control sera to detect novel bio-
markers of interest in RR sera. Briefly, the membrane
was rinsed in 70% ethanol, rinsed in distilled water and
then hydrated in Tris buffered saline with Tween20
(TBST: 10 mM Tris/Cl pH7.6, 150 mM NaCl, 0.1%
Tween20) and then immersed in the provided blocking
solution. After overnight incubation at 4°C, the mem-
brane was washed three times at 15 min intervals with
TBST and then immersed in the blocking solution. The
RR sera and control sera with unrelated autoantibody
activity were diluted 1/100 in the blocking solution and
separately applied to the membrane, incubated for 2 hr
at room temperature, washed in three changes of TBST
and then in TBS to remove the detergent. Horse radish
peroxidase (HRP)-conjugated anti-human or anti-mouse
antibodies (Jackson ImmunoResearch Lab, West Grove,
PA), was diluted 1/10,000 according to the manufac-
turer’s protocol and the bound antibodies visualized with
enhanced chemiluminescence western blotting reagents
(Amersham Biosciences, Baie d’urfe, Quebec). The react-
ive peptides were identified by referring to an array iden-
tification grid provided by the manufacturer and were
distinguished from non-specific and unrelated peptides
by comparison to the control sera.
Statistical analyses
Demographic, clinical and histologic characteristics of
the study cohort were described using the median [inter-
quartile range (IQR)] and proportions. Comparisons be-
tween groups (e.g. RR antibody positive versus negative)
employed Fisher’s exact tests for categorical variables
and Mann–Whitney tests for continuous. Univariate and
multivariate logistic regression analyses examined pre-
dictors of RR antibody positivity. Due to the limited
number of RR antibody positive cases, the multivariate
model included only age, gender, HCV genotype and
prior antiviral treatment. All statistical analyses were
performed using Stata version 10.1 software (Stata Corp.,
College Station, TX, USA). Two-sided P-values less than
0.05 were considered statistically significant.
Results
Study population
The characteristics of the study population are outlined
in Table 1. The median age of the 315 HCV-infected pa-
tients was 51 years (IQR 45–54); 61% were male, 76%
were infected with HCV genotype 1, and 45% had ac-
quired HCV via injection drug use. In total, 14 patients
(4.4%) had previously been treated with IFN-basedtherapy, 3 with IFN monotherapy and 11 with IFN and
ribavirin combination therapy. All treated patients
achieved an SVR. Liver biopsies revealed moderate to
severe necroinflammatory activity (A2-3) and fibrosis
(F2-4) in 72% and 66% of patients, respectively.
Rods and rings (RR) antibodies
IIF on HEp-2 cell substrates from INOVA Diagnostics
revealed the presence of the RR staining pattern in
15/315 (4.8%) sera (Figure 1a). However, when the
sera were retested on ImmunoConcepts HEp-2000
substrate the RR staining pattern was not observed
(not shown). None of the various cell fixatives tested (2%
buffered paraformaldehyde/Triton X permeabilization,
acetone, methanol, acetone:methanol mixtures) produced
the RR pattern in commercially available multi-passaged
HEp-2 or HeLa cells. Considering that the staining might
be related to a specific subclone of cells, HEp-2 cells
known to produce the RR pattern were obtained from
Figure 1 a) Indirect Immunofluorescence (IIF) on HEp-2 cells of
a prototype human serum with autoantibodies directed to rods
(blue arrows, ~3-10 μm in length) and rings (red arrows,
2–5 μm diameter) (RR). b) Chinese hamster ovary cells (CHO)
constitutively express multiple cytoplasmic structures/cell primarily
represented as rods of various lengths. Fixation 3.5%
paraformaldehyde; nuclei counterstained blue with DAPI.
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tured under identical conditions. In these cells, RR
staining identical to that illustrated in Figure 1 was
seen with a variety of fixation protocols but was best
preserved by fixation in 2% buffered paraformaldehyde.
However, with 2 to 3 successive cell passages the RR
pattern disappeared. Of the other cell lines tested (i.e. CHO
and HeLa) only CHO cells were found to constitutively
produce RR represented primarily as numerous cytoplas-
mic rod- or cane-like like structures of various lengths
(Figure 1b). Of note, treatment of HeLa and HEp-2 cells
with 1 μM ribavirin for 3 hours induced the formation of
RR in HeLa and HEp-2 cell lines.
Other autoantibodies, anti-IMPDH2 and candidate RR
antibody targets
A total of 281 (89%) HCV sera tested positive for auto-
antibodies by IIF on HEp-2 substrates; a nuclear staining
pattern was the most common (76%, 238/315). Only five
patients (2%) had an AMA IIF staining pattern. When10 RR IIF positive sera were tested by ALBIA, only 1
had antibodies to IMPDH2 and none reacted with
CTSP1. Neither IMPDH2 nor CTPS1 antibodies were
detected in the PBC, SLE, or normal control sera.
When the protein microarray was screened with the
RR sera and compared to results from normal controls
and unrelated autoantibodies, a number of targets of
interest were identified (Table 2). The strongest and
most consistent signals were derived from four separate
clones all related to Myc-associated zinc finger protein
(MAZI: SWISSPROT Accession # P56270). In addition,
reactivity to voltage-dependent anion channel 1 (VDAC1),
ankyrin repeat and sterile alpha motif domain containing
6 (ANKS6), ARP1 actin-related protein 1 homolog A and
three unnamed peptides of unknown function.
Clinical associations of rods and rings (RR) antibody
positivity
As shown in the Table 3, HCV-infected patients with
and without RR antibodies had similar demographic
and clinical characteristics including age, gender, infec-
tion with HCV genotype 1, mode of HCV acquisition,
serum ALT concentration, platelet count, and severity
of necroinflammation and fibrosis. Positivity for other
autoantibodies including ANA and AMA IIF staining
patterns did not differ between RR positive and nega-
tive cases. However, RR antibody-positive patients were
significantly more likely to have previously received
IFN-based treatment (33% vs. 3%; OR 16.2 [95% CI 4.6-
57.1]; P<0.0005). Whereas 5 of 11 (45%) patients
treated with IFN and ribavirin combination were RR
antibody positive, none of the 3 patients who received
IFN monotherapy had RR antibodies (P=0.26). In a
multivariate logistic regression analysis including age,
sex, and HCV genotype, prior IFN treatment was the
only independent predictor of RR antibody positivity
(OR 20.5 [95% CI 5.1-83.2]; P<0.0005). Since all pa-
tients treated with IFN achieved an SVR, the effect of
treatment success on the presence of RR autoantibodies
could not be determined.
Discussion
HCV infection is associated with a wide spectrum of im-
mune reactions, some of which are reflected by the pres-
ence of organ and non-organ specific autoantibodies.
Possible mechanisms for the production of autoanti-
bodies include molecular mimicry, an interaction of
the HCV with B lymphocytes promoting B cell prolif-
eration and activation, or direct infection of immunocytes
by HCV [48-52]. In addition, patients receiving interferon
and/or ribavirin therapy may have accelerated pre-existing
autoimmune diseases, or de novo occurrence of
autoimmune disorders or autoantibody production
[26,31,53-58].
Table 2 Potential RR autoantibody targets indentified on a protein/peptide microarray






Alternate name: Purine- binding
transcription factor (ZF87) (ZIF87).
Source: SWISSPROT; Acc:P56270
C2H2-type zinc fingers; transcription
initiation and termination; purine
metabolism [39,40]
4+
MPMGp800O22578 Homo sapiens VDAC1 Outer mitochondrial membrane; role
in apoptosis and cancer; interacts with
amyloid and tau role in Alzheimer’s [41-43]
3+
MPMGp800A24548 Homo sapiens ARM and sterile
alpha motif domain containing
6 (ANKS6)
ARM participate in protein folding and
found in ~6% of eukaryotic proteins
[44,45]
2+
MPMGp800L08582 Homo sapiens ARP1 – homolog
A (ACTR1A)
Major subunit of dynactin; molecular






Unknown proteins Unknown 2 – 3+
*Reactivity = the intensity of immunoreactivity with proteins on the microarray which were graded from 0 (no reactivity) to 4 (high intensity).
Abbreviations: ARM, ankyrin repeat motif; ARP, actin-related protein; ATP, adenosine triphospate; MAZI, Myc-associated zinc finger protein; NuMA, nuclear mitotic
apparatus (NuMA) protein; VDAC1, voltage-dependent anion channel 1.
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been reported in patients with HCV infection character-
ized by rods (~3-10 μm in length) and rings (2–5 μm
diameter) localized to the cytoplasm of certain cell lines
and expresed throughout the cell cycle [32-34]. Other
studies have determined that this IIF pattern is associ-








Median age, yrs 51 (44–54) 51 (46–61) 0.38
Male gender 61% (182) 73% (11) 0.42
HCV genotype 1 76% (228) 73% (11) 0.76
Prior injection drug
use
45% (134) 47% (7) 1.00
Prior HCV treatment 3% (9) 33% (5) <0.0005
Biochemical data †
ALT, IU/L 65 (42–110) 52 (24–80) 0.16
Platelets, x109/L 202 (167–243) 182 (134–245) 0.38
Histologic characteristics
A2-3 necroinflammation 73% (218) 53% (8) 0.14
F2-4 fibrosis 66% (198) 67% (10) 1.00
Autoantibodies
ANA positive 89% (266) 100% (15) 0.39
AMA positive 2% (5) 0% (0) 1.00
Abbreviations: ANA, antinuclear antibodies; AMA, anti-mitochondrial
antibodies; RR, Rods and Rings. † ALT and platelets missing in 10 and 5
patients, respectively.[32,33,59]. In our study we confirmed that IMPDH2 re-
acts with a minority of HCV sera, a finding in keeping
with reports by others [33,59]. Although CTSP1 was lo-
calized to RR [33], it does not appear to be a primary
target of human autoantibodies as none of our sera in
this study or human sera in a previous study [33] reacted
with the purified CTSP1 protein.
While the frequency of the reactivity to IMPDH2 in
the present study is less than previously reported
[32,33,59], it is clear from studies to date that other
autoantibody targets remain to be identified. To address
this possibility, we probed a commercially available pro-
tein and peptide microarray and identified a number of
unique potential autoantibody targets (Table 2), where
the Myc-associated zinc finger protein (MAZI) is of par-
ticular interest [39]. There is evidence that MAZI, which
contains six C2H2-type zinc fingers, functions as a tran-
scription factor with dual roles in transcription initiation
and termination [40]. While the cellular localization has
not been definitively determined, it is presumed to be
primarily localized to the nucleus, although in brains of
Alzheimer disease patients it is localized to plaque-like
structures in the cytoplasm [60]. Of note, MAZI is
expressed in kidney, liver and brain and it is a purine
binding transcription factor. The latter feature is of par-
ticular interest because of its potential relation to inosine
metabolism and IMPDH2 previously identified RR auto-
antibody targets [32,33,59].
The actin-related protein Arp1 (or centractin) is the
major subunit of dynactin, a key component of the cyto-
plasmic dynein molecular motor [46]. Under certain
conditions Arp1 has high homology to conventional
actin, which has been shown to polymerize [46]. Arp1 is
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target, the nuclear mitotic apparatus protein (NuMA)
[61]. Likewise, the ankyrin repeat motif (ARM) identified
as part of the sterile alpha motif domain containing 6
(ANKS6) protein is of interest. ARMs are typically com-
prised of 33 residues and are structurally represented as
two alpha helices separated by loops [44,45]. ARM is
also one of the most common protein–protein interac-
tions that mediate protein-protein interactions and sev-
eral unique aspects of protein folding [44,45]. Ankyrin
repeats appear in virtually all organisms but are most
abundant in eukaryotic cells where they are found in 6%
of proteins of diverse function such as transcriptional
initiators, cell cycle regulators, cytoskeleton, ion trans-
porters, and signal transducers. The voltage-dependent
anion channel 1 (VDAC1) localized to the outer mito-
chondrial membrane has been shown to control meta-
bolic interactions between mitochondria and the rest of
the cell [41]. VDAC1 has been implicated in the control
of apoptosis, including via its interaction with the pro-
and anti-apoptotic proteins [41,42] and due to an abnor-
mal interaction with amyloid beta and phosphorylated
tau, is implicated in mitochondrial dysfunction in
Alzheimer’s disease [43]. VDAC1 also contributes to the
metabolic phenotype of cancer cells as reflected by its
over-expression in many cancer types [41]. Whereas
these candidate target autoantigens have common struc-
tural and functional properties (i.e. purine metabolism
and protein folding, aggregation and polymerization),
additional studies are needed to establish immunoassays
and determine the prevalence of antibodies to these
novel targets identified in our study of index RR sera.
In our study of various cell lines, commercially avail-
able HEp-2 substrates from INOVA Diagnostics and
CHO cells maintained in our own tissue culture facility
constitutively expressed RR. Others have also reported
that the HEp-2 substrate provided by INOVA seems to
be unique in demonstrating “out of the box” RR staining
[34]. Of interest, a HEp-2 cell line obtained from Dr.
Edward K.L. Chan, one of the first to report the RR pat-
tern, produced the RR pattern but after 2 to 3 passages of
these cells, RR became undetectable. This suggests that
under certain growth or tissue culture conditions, RR
expression can either be diminished or facilitated. How-
ever, when a variety of tissue culture protocols including
various antibiotics, media and heat shock were used, we
were unable to demonstrate RR formation. Since tissue
culture and fixation protocols are considered a trade
secret by manufacturers of HEp-2 diagnostic substrates,
the reasons for this finding are not fully understood. As
reported by others [32,34], we confirmed that the RR
pattern is restored after cells are treated with ribavirin.
Of interest, ribavirin is likely not an obligatory reagent in
all cells since we are the first to report that CHO cells,constitutively and without adding exogenous ribavirin,
express similar immunoreactive RR structures.
In the present study, the 5% frequency of RR autoanti-
bodies in our HCV cohort is lower than the 20-35%
prevalence previously described in HCV sera [32,34].
The finding of antibodies to RR appears to be relatively
specific because we did not identify any RR autoanti-
bodies in PBC or SLE sera. Retrospective chart review
did not find an association between RR autoantibodies with
clinical characteristics including age, gender, mode of HCV
infection, prevalence of HCV genotype 1, serum ALT con-
centration, platelet count, severity of necroinflammation
and fibrosis or the presence of either ANA or AMA. How-
ever, both uni- and multi-variate analysis showed that prior
HCV IFN and ribavirin treatment was the only independ-
ent predictor of RR antibody positivity. Since none of the
patients treated with IFN monotherapy had RR autoanti-
bodies, RR autoantibodies seems to only be present in
HCV patients treated with combination IFN and ribavirin
therapy. This is supported by studies reported here and by
others showing that RR are induced after treatment of cell
lines with ribavirin, but not IFN [33]. These results also
confirm previous reports that RR autoantibodies were sig-
nificantly associated with prior IFN/ribavirin treatment
[34]. Other studies have shown that anti-RR antibodies
were not present at disease baseline, but appeared during
IFN/ribavirin therapy and were more often detected in
non-responder/relapsers than in responder patients [59].
Nevertheless, it is clear the antibodies to RR are seen in pa-
tient sera that have no obvious HCV infections or treat-
ment with ribavirin or IFN [32], suggesting that other
mediators are likely involved in induction of the B cell
anti-RR response. As all of our patients treated for HCV
achieved an SVR, we were unable to assess this in our
study but is amenable to more effective analysis in multi-
center studies of larger cohorts because it may be a bio-
marker for poor response to therapy. In addition, the effect
of ‘triple therapy’ on the induction of RR autoantibodies,
has yet to be investigated.
Limitations to our study include the small sample size
of HCV treated patients and the majority of our cohort
were not treated with IFN/ribavirin at the time of sera
collection (convenience sample as described above). How-
ever, this may be an advantage in showing the importance
of IFN/ribavirin as a triggering or modulating factor in
the induction of these novel autoantibodies as it does sup-
port previous studies, that RR are primarily seen in IFN/
ribavirin treated patients thus explaining our relatively
low frequency of RR as compared to previous reports.
The fact that all treated patients achieved an SVR, limited
our ability to fully identify the relationship of RR autoanti-
bodies to treatment outcomes. In addition, this is a retro-
spective study without longitudinal sera samples (i.e. pre,
during, and post therapy).
Stinton et al. BMC Gastroenterology 2013, 13:50 Page 7 of 8
http://www.biomedcentral.com/1471-230X/13/50Conclusion
In conclusion, a novel cytoplasmic autoantibody staining
pattern, rods and rings (RR) has recently been reported
in patients with HCV infection [32,34]. We identified
this pattern in 5% of our HCV cohort and found that
prior IFN and ribavirin treatment was significantly asso-
ciated with RR autoantibody positivity. Only a minority
of our RR sera reacted with IMPDH2 and none reacted
with CSP1, suggesting more effort is required in identify-
ing the related target autoantigens. Further investiga-
tions are warranted to further determine the clinical,
pathogenic, and prognostic significance of autoanti-
bodies directed against RR.
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